Biopharma

Ascendis Pharma unveiled an ambitious 2026 roadmap, projecting significant revenue growth driven by YORVIPATH and SKYTROFA. The company anticipates around €720 million in revenue for 2025 and aims for €500 million in operating cash flow by 2026. Key pipeline advancements include potential approval for TransCon CNP and promising combination therapies. Strategic collaborations and a $120 million share repurchase program underscore Ascendis’ transition to a global biopharma leader.